



OPEN ACCESS

EDITED BY

Keun Hwa Lee,
Hanyang University, Republic of Korea

REVIEWED BY

Jeong Rae Yoo,
Jeju National University, Republic of Korea

*CORRESPONDENCE

Chenxiao Jiang
✉ sharejcx@163.com
Jun Wang
✉ wjgaogou@aliyun.com
Chao Wu
✉ dr.wu@nju.edu.cn

[†]These authors have contributed equally to this work

RECEIVED 08 February 2024

ACCEPTED 25 March 2024

PUBLISHED 05 April 2024

CITATION

Liu Y, Tong H, He F, Zhai Y, Wu C, Wang J and Jiang C (2024) Corrigendum: Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications.
Front. Immunol. 15:1383797.
doi: 10.3389/fimmu.2024.1383797

COPYRIGHT

© 2024 Liu, Tong, He, Zhai, Wu, Wang and Jiang. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications

Yun Liu^{1†}, Hanwen Tong^{1†}, Fei He^{1†}, Yu Zhai¹, Chao Wu^{2*}, Jun Wang^{1*} and Chenxiao Jiang^{3*}

¹Department of Emergency Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Infectious Disease, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

KEYWORDS

intravenous immunoglobulin, mortality, severe fever with thrombocytopenia syndrome, neurological complications, dosage, duration

A Corrigendum on

Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications

By Liu Y, Tong H, He F, Zhai Y, Wu C, Wang J and Jiang C (2023). *Front. Immunol.* 14:1118039. doi: 10.3389/fimmu.2023.1118039

In the published article, there was an error in [Figure 2](#) as published. The unit of IVIG dosage was displayed as “mg”. The corrected [Figure 2](#) and its caption Comparison of (A) IVIG dosage and (B) IVIG duration between the survival group and the death group. **P < 0.01. appear below.

In the published article, there was an error in [Figure 4](#) as published. The unit of IVIG dosage was displayed as “mg”. The corrected [Figure 4](#) and its caption Kaplan–Meier curves estimating 28-day mortality in SFTS patients based on (A) IVIG dosage and (B) IVIG duration. appear below.

In the published article, there was an error in [Table 1](#) as published. The unit of IVIG dosage was displayed as “mg”. The corrected [Table 1](#) and its caption Baseline clinical characteristics and laboratory parameters of patients in the survival and death groups. appear below.

In the published article, there was an error. The unit of IVIG dosage was displayed as “mg”. A correction has been made to **Introduction**, Paragraph Number 161. This sentence previously stated:

“Ultimately, we determined that an IVIG dosage of more than or equal to 80 mg through a prolonged treatment duration of five or more days serves as a good prognosis predictor in SFTS with neurological symptoms.”

The corrected sentence appears below:

“Ultimately, we determined that an IVIG dosage of more than or equal to 80 g through a prolonged treatment duration of five or more days serves as a good prognosis predictor in SFTS with neurological symptoms.”

A correction has been made to **Results**, Paragraph Number 694. This sentence previously stated:

“Patients with an IVIG dosage of more than or equal to 80 mg (Figure 4A) and an IVIG duration of 5 days or more (Figure 4B) had higher survival rates.”

The corrected sentence appears below:

“Patients with an IVIG dosage of more than or equal to 80 g (Figure 4A) and an IVIG duration of 5 days or more (Figure 4B) had higher survival rates.”

A correction has been made to **Discussion**, Paragraph Number 884. This sentence previously stated:

“In this study, our findings suggested that higher dosages (≥ 80 mg) and a prolonged duration of IVIG treatment may improve the prognosis of SFTS patients.”

The corrected sentence appears below:

“In this study, our findings suggested that higher dosages (≥ 80 g) and a prolonged duration of IVIG treatment may improve the prognosis of SFTS patients.”

The authors apologize for the errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 2 Comparison of (A) IVIG dosage and (B) IVIG duration between the survival group and the death group. **P < 0.01.




FIGURE 4 Kaplan–Meier curves estimating 28-day mortality in SFTS patients based on (A) IVIG dosage and (B) IVIG duration.

TABLE 1 Baseline clinical characteristics and laboratory parameters of patients in the survival and death groups.

Variable	Survival (n = 36)	Death (n = 26)	P-value
Demographics			
Age, years	67 (54-73)	71 (58-76)	0.199
Male, n (%)	18 (50.0%)	11 (42.3%)	0.549
Chronic comorbidities, n (%)			
Hypertension	11 (30.6%)	10 (38.5%)	0.516
Diabetes mellitus	3 (8.3%)	2 (7.7%)	1.000
Malignancy	1 (2.78%)	0 (0%)	1.000
CAD	1 (2.78%)	0 (0%)	1.000
COPD	0 (0%)	1 (3.85%)	0.419
Clinical manifestations, n (%)			
Nausea	12 (33.3%)	7 (26.9%)	0.589
Vomiting	10 (27.8%)	9 (34.6%)	0.564
Celiacgia	4 (11.1%)	2 (7.7%)	0.653
Diarrhea	17 (47.2%)	10 (38.5%)	0.492
Unintelligible speech	1 (2.8%)	3(11.5%)	0.300
Dizziness and headache	18 (50.0%)	6 (23.1%)	0.032
Cough	9 (25.0%)	4 (15.4%)	0.359
Sputum	7 (19.4%)	3 (11.5%)	0.627
Chest tightness	3 (8.3%)	3 (11.5%)	0.689
Rash	6 (16.7%)	1 (3.8%)	0.222
Lymphadenopathy	13 (36.1%)	7 (26.9%)	0.445
Bleeding spots on the skin	7 (19.4%)	9 (34.6%)	0.178
Laboratory parameters			
WBC count, median (IQR), $\times 10^9/L$	2.5 (1.8-4.6)	2.7 (1.7-3.7)	0.898
ANC count, median (IQR), $\times 10^9/L$	1.7 (1.0-2.9)	2.1 (1.2-2.8)	0.668
ALC count, median (IQR), $\times 10^9/L$	0.7 (0.4-0.9)	0.5 (0.3-0.6)	0.042
NLR, median (IQR)	2.2 (1.5-6.1)	3.3 (1.9-9.1)	0.136
RDW, median (IQR), %	13.2 (12.8-13.5)	13.6 (12.8-14.3)	0.071
PLT count, median (IQR), $\times 10^9/L$	44.5 (33.8-61.3)	39.5 (29.0-58.5)	0.480
PLR, median (IQR)	65.5 (39.3-146)	89.6 (67.5-145.0)	0.248
PT, median (IQR), s	12.0 (11.2-12.6)	12.4 (11.7-13.0)	0.123
APTT, median (IQR), s	41.4 (33.6-46.3)	48.5 (37.6-61.1)	0.009

(Continued)

TABLE 1 Continued

Variable	Survival (n = 36)	Death (n = 26)	P-value
TT, median (IQR), s	22.8 (21.1-27.7)	26.9 (21.8-57.9)	0.057
D-dimer, median (IQR), mg/L	3.8 (2.3-9.2)	9.9 (3.4-22.6)	0.018
ALT, median (IQR), U/L	69.6 (54.3-97.2)	75.3 (50.5-90.5)	0.881
AST, median (IQR), U/L	172.5 (93.4-312.9)	222.0 (114.1-321.8)	0.304
ALB, median (IQR), g/L	32.0 (28.7-35.7)	31.7 (29.1-34.1)	0.775
TBIL, median (IQR), $\mu\text{mol/L}$	11.0 (8.6-13.9)	7.7 (5.8-11.5)	0.066
SCr, median (IQR), $\mu\text{mol/L}$	72.5 (48.8-89.6)	82 (67.5-123.6)	0.090
BUN, median (IQR), mmol/L	5.2 (3.5-7.1)	5.9 (4.8-10.6)	0.061
UA, median (IQR), $\mu\text{mol/L}$	306 (236-347)	342 (231-463)	0.471
IVIG usage			
IVIG dosage, g	95.0 (57.5-100.0)	60.0 (40.0-100.0)	0.066
IVIG duration, d	5 \pm 2	4 \pm 2	0.003
Additional information			
Time from onset to arriving in hospital, d	7 \pm 3	7 \pm 2	0.317
Time from onset to IVIG treatment, d	9 \pm 3	9 \pm 3	0.677

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; RDW, red cell volume distribution width; PLT, platelet; PLR, platelet-to-lymphocyte ratio; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; SCr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; IVIG, intravenous immunoglobulin; IQR, interquartile range.